These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34102381)

  • 1. A machine learning approach to screen for preclinical Alzheimer's disease.
    Gaubert S; Houot M; Raimondo F; Ansart M; Corsi MC; Naccache L; Sitt JD; Habert MO; Dubois B; De Vico Fallani F; Durrleman S; Epelbaum S;
    Neurobiol Aging; 2021 Sep; 105():205-216. PubMed ID: 34102381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease.
    Gaubert S; Raimondo F; Houot M; Corsi MC; Naccache L; Diego Sitt J; Hermann B; Oudiette D; Gagliardi G; Habert MO; Dubois B; De Vico Fallani F; Bakardjian H; Epelbaum S;
    Brain; 2019 Jul; 142(7):2096-2112. PubMed ID: 31211359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
    Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
    J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings.
    Jack CR; Wiste HJ; Weigand SD; Knopman DS; Mielke MM; Vemuri P; Lowe V; Senjem ML; Gunter JL; Reyes D; Machulda MM; Roberts R; Petersen RC
    Brain; 2015 Dec; 138(Pt 12):3747-59. PubMed ID: 26428666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
    Chételat G; Fouquet M
    Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI-based Alzheimer's disease-resemblance atrophy index in the detection of preclinical and prodromal Alzheimer's disease.
    Liu W; Au LWC; Abrigo J; Luo Y; Wong A; Lam BYK; Fan X; Kwan PWL; Ma HW; Ng AYT; Chen S; Leung EYL; Ho CL; Wong SHM; Chu WC; Ko H; Lau AYL; Shi L; Mok VCT;
    Aging (Albany NY); 2021 May; 13(10):13496-13514. PubMed ID: 34091443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.
    Wirth M; Villeneuve S; Haase CM; Madison CM; Oh H; Landau SM; Rabinovici GD; Jagust WJ
    JAMA Neurol; 2013 Dec; 70(12):1512-9. PubMed ID: 24166579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults.
    Okonkwo OC; Xu G; Dowling NM; Bendlin BB; Larue A; Hermann BP; Koscik R; Jonaitis E; Rowley HA; Carlsson CM; Asthana S; Sager MA; Johnson SC
    Neurology; 2012 May; 78(22):1769-76. PubMed ID: 22592366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Ayutyanont N; Roontiva A; Thiyyagura P; Protas H; Joshi AD; Sabbagh M; Sadowsky CH; Sperling RA; Clark CM; Mintun MA; Pontecorvo MJ; Coleman RE; Doraiswamy PM; Johnson KA; Carpenter AP; Skovronsky DM; Reiman EM
    Neurobiol Aging; 2013 Jan; 34(1):1-12. PubMed ID: 22633529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease.
    Spasov S; Passamonti L; Duggento A; Liò P; Toschi N;
    Neuroimage; 2019 Apr; 189():276-287. PubMed ID: 30654174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of family history for Alzheimer biomarker abnormalities in the adult children study.
    Xiong C; Roe CM; Buckles V; Fagan A; Holtzman D; Balota D; Duchek J; Storandt M; Mintun M; Grant E; Snyder AZ; Head D; Benzinger TL; Mettenburg J; Csernansky J; Morris JC
    Arch Neurol; 2011 Oct; 68(10):1313-9. PubMed ID: 21987546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease.
    Nakamura A; Cuesta P; Fernández A; Arahata Y; Iwata K; Kuratsubo I; Bundo M; Hattori H; Sakurai T; Fukuda K; Washimi Y; Endo H; Takeda A; Diers K; Bajo R; Maestú F; Ito K; Kato T
    Brain; 2018 May; 141(5):1470-1485. PubMed ID: 29522156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'.
    Galluzzi S; Marizzoni M; Babiloni C; Albani D; Antelmi L; Bagnoli C; Bartres-Faz D; Cordone S; Didic M; Farotti L; Fiedler U; Forloni G; Girtler N; Hensch T; Jovicich J; Leeuwis A; Marra C; Molinuevo JL; Nobili F; Pariente J; Parnetti L; Payoux P; Del Percio C; Ranjeva JP; Rolandi E; Rossini PM; Schönknecht P; Soricelli A; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
    J Intern Med; 2016 Jun; 279(6):576-91. PubMed ID: 26940242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.
    Vanitallie TB
    Metabolism; 2013 Jan; 62 Suppl 1():S30-3. PubMed ID: 23021038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.